Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
This overview explains risk parity investing and how allocating risk rather than capital can influence retirement portfolio stability.
26,917 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Oracle posted stronger-than-expected cloud results for Q3 FY2026, sending ORCL higher and helping the stock lead tech...
The housing market is showing early momentum for 2026, with rising existing sales and persistent mortgage demand, yet...
Atlassian shares remain under pressure as the company drives cost cuts and pivots to a cloud-focused model. Analysts ...
Wedbush boosts its Micron price target to $500, arguing demand remains healthy after the Chinese New Year. The upgrad...
Galaxy Digital warns the CLARITY Act may stall in 2026 without a timely committee vote, with lawmakers juggling other...
This article breaks down MSGM earnings and what investors should watch in motorsport games. Learn how revenue streams...
General Mills sits near $39 after a soft quarter, boosting the dividend to about 6.3%. Retirees eyeing general mills’...
Analysts push a higher target for NVIDIA as demand for Blackwell and Vera Rubin accelerates. The latest guidance sign...
Pre-marketing for homes, dubbed coming soon listings, has moved from niche tests to a nationwide driver of housing de...
Intel and AMD slid on Friday as AI competition intensifies and supply-chain tensions weigh on the sector, despite str...
Lenders posted healthier profits per loan in Q3 2025, but declined loans still drain resources. A new declined loan a...